• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.

作者信息

Rejeski Kai, Wu Zhijie, Blumenberg Viktoria, Kunz Wolfgang G, Müller Susanna, Kajigaya Sachiko, Gao Shouguo, Bücklein Veit L, Frölich Lisa, Schmidt Christian, von Bergwelt-Baildon Michael, Feng Xingmin, Young Neal S, Subklewe Marion

机构信息

Department of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany.

Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.

出版信息

Blood. 2022 Nov 17;140(20):2175-2179. doi: 10.1182/blood.2022017015.

DOI:10.1182/blood.2022017015
PMID:35776908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9837444/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6805/9837444/8742aca0b2a8/BLOOD_BLD-2022-017015-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6805/9837444/a03214b663e5/BLOOD_BLD-2022-017015-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6805/9837444/c928f3449c26/BLOOD_BLD-2022-017015-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6805/9837444/8742aca0b2a8/BLOOD_BLD-2022-017015-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6805/9837444/a03214b663e5/BLOOD_BLD-2022-017015-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6805/9837444/c928f3449c26/BLOOD_BLD-2022-017015-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6805/9837444/8742aca0b2a8/BLOOD_BLD-2022-017015-gr2.jpg

相似文献

1
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.接受CD19嵌合抗原受体T细胞（CAR-T）疗法治疗Richter转化型弥漫性大B细胞淋巴瘤（DLBCL）后出现骨髓衰竭患者的寡克隆T细胞扩增
Blood. 2022 Nov 17;140(20):2175-2179. doi: 10.1182/blood.2022017015.
2
Safer CAR T-Cell Therapy.更安全的嵌合抗原受体T细胞疗法
JAMA. 2019 Jun 11;321(22):2155. doi: 10.1001/jama.2019.7551.
3
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.CD19 和 CD20 靶向嵌合抗原受体 T 细胞联合给药治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 II 期临床试验。
Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.
4
CAR T cells - what have we learnt?嵌合抗原受体T细胞——我们学到了什么？
Nat Rev Clin Oncol. 2017 Dec 15;15(1):1. doi: 10.1038/nrclinonc.2017.196.
5
Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.在一项针对小儿急性淋巴细胞白血病的 I 期研究中，证明了移植的嵌合抗原受体修饰的 CD19 特异性 T 细胞具有持久的抗 CD19 活性。
Hematol Oncol. 2019 Dec;37(5):601-608. doi: 10.1002/hon.2672. Epub 2019 Sep 15.
6
Beyond CD19 CAR-T cells in lymphoma.淋巴瘤中超越 CD19 CAR-T 细胞疗法。
Curr Opin Immunol. 2022 Feb;74:46-52. doi: 10.1016/j.coi.2021.09.009. Epub 2021 Nov 17.
7
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.体内第二代与第三代 CD19 特异性 CAR-T 细胞在 B 细胞非霍奇金淋巴瘤中的命运和活性。
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
8
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.嵌合抗原受体 T 细胞疗法治疗小儿 B-ALL：缩小早期和长期结局之间的差距。
Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.
9
Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.抗CD19嵌合抗原受体T细胞疗法后B细胞发育不全早期丧失的维持治疗。
Blood Adv. 2024 Apr 23;8(8):1959-1963. doi: 10.1182/bloodadvances.2023011168.
10
Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.转座子介导的源自 CD45RA 阳性外周血单个核细胞的嵌合抗原受体 T 细胞具有强大且持久的抗白血病功能。
Front Immunol. 2022 Jan 27;13:770132. doi: 10.3389/fimmu.2022.770132. eCollection 2022.

引用本文的文献

1
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.免疫效应细胞相关的血液毒性：机制、临床表现及管理策略。
Haematologica. 2025 Jun 1;110(6):1254-1268. doi: 10.3324/haematol.2024.286027. Epub 2025 Feb 20.
2
Incorporating Immunotherapy with Radiotherapy for Lymphomas.淋巴瘤的免疫疗法与放射疗法联合应用
Lymphatics. 2023 Dec;1(3):273-286. doi: 10.3390/lymphatics1030018. Epub 2023 Dec 7.
3
Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids.

本文引用的文献

1
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.嵌合抗原受体 T 细胞（CAR-T）治疗后复发/难治性大 B 细胞淋巴瘤（R/R LBCL）患者的 CAR-HEMATOTOX 风险可预测严重感染和疾病进展。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2021-004475.
2
Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells.单细胞 RNA 测序与大颗粒淋巴细胞白血病 T 细胞 TCR 谱分析的结合。
Nat Commun. 2022 Apr 11;13(1):1982. doi: 10.1038/s41467-022-29175-x.
3
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
由大颗粒淋巴细胞驱动的嵌合抗原受体 T 细胞治疗后出现严重血细胞减少并对类固醇有反应。
Br J Haematol. 2025 Jan;206(1):180-185. doi: 10.1111/bjh.19822. Epub 2024 Oct 19.
4
Mechanisms and management of CAR T toxicity.嵌合抗原受体T细胞毒性的机制与管理
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.
5
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.嵌合抗原受体 T 细胞（CAR T）治疗后与免疫效应细胞相关的血液毒性：从机制到管理。
Lancet Haematol. 2024 Jun;11(6):e459-e470. doi: 10.1016/S2352-3026(24)00077-2. Epub 2024 May 8.
6
Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies.利用单细胞测序技术研究 CAR-T 细胞和白血病/淋巴瘤的转录特征。
Int J Mol Sci. 2024 Feb 19;25(4):2416. doi: 10.3390/ijms25042416.
7
Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.嵌合抗原受体 T 细胞疗法在 B 细胞淋巴瘤患者中面临的挑战。
Ann Lab Med. 2024 May 1;44(3):210-221. doi: 10.3343/alm.2023.0388. Epub 2024 Jan 11.
8
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).嵌合抗原受体 T 细胞（CAR-T）疗法治疗大 B 细胞淋巴瘤后的输血需求：预测因素和结果（DESCAR-T 研究）。
Blood Adv. 2024 Mar 26;8(6):1573-1585. doi: 10.1182/bloodadvances.2023011727.
9
Recognizing, defining, and managing CAR-T hematologic toxicities.识别、定义和管理 CAR-T 血液学毒性。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):198-208. doi: 10.1182/hematology.2023000472.
10
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.从嵌合抗原受体 T 细胞免疫疗法治疗癌症的单细胞分析中获得的见解。
Mil Med Res. 2023 Nov 8;10(1):52. doi: 10.1186/s40779-023-00486-4.
阿基仑赛注射液二线治疗大 B 细胞淋巴瘤。
N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11.
4
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.严重细胞因子释放综合征与 CD19 CAR T 细胞治疗后的血液学毒性有关。
Blood Adv. 2022 Apr 12;6(7):2055-2068. doi: 10.1182/bloodadvances.2020004142.
5
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.
6
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.CD19 靶向 CAR T 细胞治疗后骨髓衰竭导致严重光滑念珠菌全结肠炎和致命烟曲霉肺部感染 - 一例报告。
BMC Infect Dis. 2021 Jan 28;21(1):121. doi: 10.1186/s12879-020-05755-4.
7
Cytokine Storm.细胞因子风暴
N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131.
8
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.接受嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤患者的造血恢复情况。
Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509.
9
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?慢性淋巴细胞白血病中的 T 细胞：疾病的守护者还是驱动者？
Leukemia. 2020 Aug;34(8):2012-2024. doi: 10.1038/s41375-020-0873-2. Epub 2020 May 26.
10
Early and late hematologic toxicity following CD19 CAR-T cells.CD19嵌合抗原受体T细胞治疗后的早期和晚期血液学毒性
Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.